Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

By Zacks Investment ResearchStock MarketsJul 04, 2021 10:20PM ET
www.investing.com/analysis/alector-alec-up-on-tieup-with-glaxo-for-neurological-diseases-200589828
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
By Zacks Investment Research   |  Jul 04, 2021 10:20PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
RGEN
+0.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GSK
+0.96%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TRVN
+3.33%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ALEC
-5.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Shares of Alector (NASDAQ:ALEC), Inc. ALEC surged 57.1% on Friday after the company announced that it has entered into a strategic collaboration with British pharma giant GlaxoSmithKline (NYSE:GSK) GSK to jointly develop and commercialize its two clinical-stage first-in-class monoclonal antibodies for treating neurodegenerative diseases.

The companies are looking to jointly develop and co-commercialize AL001 and AL101, which are designed to elevate levels of progranulin, a key regulator of immune activity in the brain with links to multiple neurodegenerative disorders.

In fact, Alector's has rallied 132.7% so far this year compared with the industry’s increase of 2.1%.

Zacks Investment Research
Zacks Investment Research
Image Source: Zacks Investment Research


With this deal, the companies are looking to leverage Alector’s expertise in immuno-neurology with Glaxo’s focus on immunology and human genetics, its drug development capabilities, as well as its global footprint.

Per the deal, Alector will receive an upfront payment of $700 million from Glaxo and will also be eligible to receive up to $1.5 billion in potential milestone payments, profit sharing and royalties on net sales if a product is commercialized from the above collaboration.

Alector will lead the development of AL001 and AL101 through phase II proof-of-concept, after which both companies will share development responsibilities and costs for the subsequent studies on AL001 and AL101.

Both Alector and Glaxo will co-commercialize and share profits in the United States, while Glaxo will solely retain commercialization rights for AL001 and AL101 in ex-U.S. markets.

The closure of the deal depends on customary closing conditions, including reviews by the regulatory agencies under the Hart-ScottRodino Act.

Please note that enrollment is currently ongoing in a phase III study which is evaluating AL001 in people at risk with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The candidate is also being investigated in a phase II study for treating symptomatic FTD patients with a mutation in the C9orf72 gene. A phase II study on AL001 for treating amyotrophic lateral sclerosis or ALS is expected to begin in the second half of 2021.

AL101 is in early-stage development, and has been designed for treating more common neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease.

If successfully developed and upon potential approval, both AL001 and AL101 can lend a significant boost to the scientific community by providing a novel therapeutic approach for the treatment of neurodegenerative diseases. It will also help Glaxo to get access to a promising clinical program in immuno-neurology, thereby diversifying its product pipeline.

Zacks Rank & Stocks to Consider

Alector currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Repligen (NASDAQ:RGEN) Corporation RGEN and Trevena (NASDAQ:TRVN), Inc. TRVN, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Repligen’s earnings estimates have been revised 18.3% and 14.7% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 5.4% year to date.

Trevena’s loss per share estimates have narrowed 6.4% for 2021 and 3.7% for 2022 over the past 60 days.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

Repligen Corporation (RGEN): Free Stock Analysis Report

Trevena, Inc. (TRVN): Free Stock Analysis Report

Alector, Inc. (ALEC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
 

Related Articles

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email